Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2021;1311:127–136. doi: 10.1007/978-3-030-65768-0_9

The Heterogeneity of Liver Cancer Metabolism.

Javier Salazar, Anne Le
PMCID: PMC9703211  PMID: 34014539

Abstract

Primary liver cancer is the fourth leading cause of cancer death around the world. Histologically, it can be divided into two major groups, hepatocellular carcinoma (75% of all liver cancer) and intrahepatic cholangiocarcinoma (15% of all liver cancer) [1, 2]. Primary liver cancer usually happens in liver disease or cirrhosis patients [1], and the risk factors for developing HCC depend on the etiology [3] and the country of provenance [1]. There is an urgent need for an accurate diagnostic test given the high proportion of false positives and false negatives for alpha-fetoprotein (AFP), a common HCC biomarker [4]. Due to often being diagnosed in advanced stages, HCCrelated deaths per year have doubled since 1999 [3]. With the use of metabolomics technologies [5], the aberrant metabolism characteristics of cancer tissues can be discovered and exploited for the new biomarkers and new therapies to treat HCC [6, 7].

Full text of this article can be found in Bookshelf.

References

  1. Dasgupta, P., et al. (2020). Global trends in incidence rates of primary adult liver cancers: A systematic review and meta-analysis. Frontiers in Oncology, 10, 171. doi: 10.3389/fonc.2020.00171. [DOI] [PMC free article] [PubMed]
  2. Lin, H. S., et al. (2019). Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform. Cancers (Basel), 11, 6. doi: 10.3390/cancers11060739. [DOI] [PMC free article] [PubMed]
  3. Kim, H. S., & El-Serag, H. B. (2019). The epidemiology of hepatocellular carcinoma in the USA. Current Gastroenterology Reports, 21(4), 17. doi: 10.1007/s11894-019-0681-x. [DOI] [PubMed]
  4. Gao, R., et al. (2015). Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma. Scientific Reports, 5, 18175. doi: 10.1038/srep18175. [DOI] [PMC free article] [PubMed]
  5. Hoang, G., Udupa, S., & Le, A. (2019). Application of metabolomics technologies toward cancer prognosis and therapy. International Review of Cell and Molecular Biology, 347, 191–223. doi: 10.1016/bs.ircmb.2019.07.003. [DOI] [PubMed]
  6. Dang, C. V., et al. (2011). Therapeutic targeting of cancer cell metabolism. Journal of Molecular Medicine (Berlin), 89(3), 205–212. doi: 10.1007/s00109-011-0730-x. [DOI] [PMC free article] [PubMed]
  7. Hirschey, M. D., et al. (2015). Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 35(Suppl), S129–S150. doi: 10.1016/j.semcancer.2015.10.002. [DOI] [PMC free article] [PubMed]
  8. Llovet, J. M., et al. (2016). Hepatocellular carcinoma. Nature Reviews. Disease Primers, 2, 16018. doi: 10.1038/nrdp.2016.18. [DOI] [PubMed]
  9. Nabi, K., & Le, A. (2021). The intratumoral heterogeneity of cancer metabolism. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_11 doi: 10.1007/978-3-030-65768-0_11. [DOI] [PMC free article] [PubMed]
  10. Antonio, M. J., Zhang, C., & Le, A. (2021). Different tumor microenvironments lead to different metabolic phenotypes. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_10 doi: 10.1007/978-3-030-65768-0_10. [DOI] [PMC free article] [PubMed]
  11. Forner, A., Llovet, J. M., & Bruix, J. (2012). Hepatocellular carcinoma. Lancet, 379(9822), 1245–1255. doi: 10.1016/S0140-6736(11)61347-0. [DOI] [PubMed]
  12. Zucman-Rossi, J., et al. (2015). Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology, 149(5), 1226–1239. e4. doi: 10.1053/j.gastro.2015.05.061. [DOI] [PubMed]
  13. Schulze, K., Nault, J. C., & Villanueva, A. (2016). Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 65(5), 1031–1042. doi: 10.1016/j.jhep.2016.05.035. [DOI] [PubMed]
  14. Bobrovnikova-Marjon, E., & Hurov, J. B. (2014). Targeting metabolic changes in cancer: Novel therapeutic approaches. Annual Review of Medicine, 65, 157–170. doi: 10.1146/annurev-med-092012-112344. [DOI] [PubMed]
  15. Wolpaw, A. J., & Dang, C. V. (2018). Exploiting metabolic vulnerabilities of cancer with precision and accuracy. Trends in Cell Biology, 28(3), 201–212. doi: 10.1016/j.tcb.2017.11.006. [DOI] [PMC free article] [PubMed]
  16. Cancer Genome Atlas Research Network. (2017). Electronic address, w.b.e. and N. Cancer genome atlas research, comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell, 169(7), 1327–1341.e23. doi: 10.1016/j.cell.2017.05.046. [DOI] [PMC free article] [PubMed]
  17. Calderaro, J., et al. (2017). Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. Journal of Hepatology, 67(4), 727–738. doi: 10.1016/j.jhep.2017.05.014. [DOI] [PubMed]
  18. Zheng, H., et al. (2018). Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology, 68(1), 127–140. doi: 10.1002/hep.29778. [DOI] [PMC free article] [PubMed]
  19. Xue, R., et al. (2016). Variable Intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology, 150(4), 998–1008. doi: 10.1053/j.gastro.2015.12.033. [DOI] [PubMed]
  20. Dang, C. V., Le, A., & Gao, P. (2009). MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clinical Cancer Research, 15(21), 6479–6483. doi: 10.1158/1078-0432.CCR-09-0889. [DOI] [PMC free article] [PubMed]
  21. Le, A., & Dang, C. V. (2013). Studying Myc’s role in metabolism regulation. Methods in Molecular Biology, 1012, 213–219. doi: 10.1007/978-1-62703-429-6_14. [DOI] [PMC free article] [PubMed]
  22. Yuneva, M. O., et al. (2012). The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metabolism, 15(2), 157–170. doi: 10.1016/j.cmet.2011.12.015. [DOI] [PMC free article] [PubMed]
  23. Bose, S., Zhang, C., & Le, A. (2021). Glucose metabolism in cancer: The Warburg effect and beyond. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_1 doi: 10.1007/978-3-030-65768-0_1. [DOI] [PMC free article] [PubMed]
  24. Li, T., Copeland, C., & Le, A. (2021). Glutamine metabolism in cancer. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_2 doi: 10.1007/978-3-030-65768-0_2. [DOI] [PMC free article] [PubMed]
  25. Wise, D. R., et al. (2008). Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proceedings of the National Academy of Sciences of the United States of America, 105(48), 18782–18787. doi: 10.1073/pnas.0810199105. [DOI] [PMC free article] [PubMed]
  26. Xu, P., et al. (2016). LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer. Genes & Development, 30(11), 1255–1260. doi: 10.1101/gad.277483.116. [DOI] [PMC free article] [PubMed]
  27. Laplante, M., & Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell, 149(2), 274–293. doi: 10.1016/j.cell.2012.03.017. [DOI] [PMC free article] [PubMed]
  28. Zimmermann, S. C., et al. (2016). Allosteric glutaminase inhibitors based on a 1,4-di(5-amino-1,3,4-thiadiazol-2-yl)butane scaffold. ACS Medicinal Chemistry Letters, 7(5), 520–524. doi: 10.1021/acsmedchemlett.6b00060. [DOI] [PMC free article] [PubMed]
  29. Rais, R., et al. (2016). Discovery of 6-diazo-5-oxo-l-norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: A potential treatment for glioblastoma. Journal of Medicinal Chemistry, 59(18), 8621–8633. doi: 10.1021/acs.jmedchem.6b01069. [DOI] [PubMed]
  30. Xiang, Y., et al. (2015). Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. The Journal of Clinical Investigation, 125(6), 2293–2306. doi: 10.1172/JCI75836. [DOI] [PMC free article] [PubMed]
  31. Le, A., et al. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metabolism, 15(1), 110–121. doi: 10.1016/j.cmet.2011.12.009. [DOI] [PMC free article] [PubMed]
  32. Elgogary, A., et al. (2016). Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 113(36), E5328–E5336. doi: 10.1073/pnas.1611406113. [DOI] [PMC free article] [PubMed]
  33. Udupa, S., et al. (2019). Upregulation of the glutaminase II pathway contributes to glutamate production upon glutaminase 1 inhibition in pancreatic cancer. Proteomics, 19(21–22), e1800451. doi: 10.1002/pmic.201800451. [DOI] [PMC free article] [PubMed]
  34. Nguyen, T., et al. (2019). Uncovering the role of N-acetyl-aspartyl-glutamate as a glutamate reservoir in cancer. Cell Reports, 27(2), 491–501. e6. doi: 10.1016/j.celrep.2019.03.036. [DOI] [PMC free article] [PubMed]
  35. Hu, H., et al. (2017). Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology, 65(2), 515–528. doi: 10.1002/hep.28887. [DOI] [PubMed]
  36. Dang, C. V. (2010). Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Research, 70(3), 859–862. doi: 10.1158/0008-5472.CAN-09-3556. [DOI] [PMC free article] [PubMed]
  37. Hur, W., et al. (2017). Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133. Scientific Reports, 7, 45557. doi: 10.1038/srep45557. [DOI] [PMC free article] [PubMed]
  38. Kim, Y. H., et al. (2017). SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget, 8(40), 68381–68392. doi: 10.18632/oncotarget.20266. [DOI] [PMC free article] [PubMed]
  39. Cassim, S., et al. (2018). Metabolite profiling identifies a signature of tumorigenicity in hepatocellular carcinoma. Oncotarget, 9(42), 26868–26883. doi: 10.18632/oncotarget.25525. [DOI] [PMC free article] [PubMed]
  40. DeWaal, D., et al. (2018). Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nature Communications, 9(1), 446. doi: 10.1038/s41467-017-02733-4. [DOI] [PMC free article] [PubMed]
  41. Fang, Z., et al. (2017). The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer. Iranian Journal of Basic Medical Sciences, 20(2), 187–192. doi: 10.22038/ijbms.2017.8246. [DOI] [PMC free article] [PubMed]
  42. Le, A., et al. (2010). Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 107(5), 2037–2042. doi: 10.1073/pnas.0914433107. [DOI] [PMC free article] [PubMed]
  43. Rajeshkumar, N. V., et al. (2015). Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Research, 75(16), 3355–3364. doi: 10.1158/0008-5472.CAN-15-0108. [DOI] [PMC free article] [PubMed]
  44. Dutta, P., et al. (2013). Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Research, 73(14), 4190–4195. doi: 10.1158/0008-5472.CAN-13-0465. [DOI] [PMC free article] [PubMed]
  45. Hirata, H., et al. (2016). Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. Cancer Research, 76(11), 3265–3276. doi: 10.1158/0008-5472.CAN-15-2601. [DOI] [PubMed]
  46. Bjornson, E., et al. (2015). Stratification of hepatocellular carcinoma patients based on acetate utilization. Cell Reports, 13(9), 2014–2026. doi: 10.1016/j.celrep.2015.10.045. [DOI] [PubMed]
  47. Park, J. K., et al. (2021). The heterogeneity of lipid metabolism in cancer. Advances in Experimental Medicine and Biology, 1311, https://doi.org/10.1007/978-3-030-65768-0_3 doi: 10.1007/978-3-030-65768-0_3. [DOI] [PMC free article] [PubMed]
  48. Arauz, J., Ramos-Tovar, E., & Muriel, P. (2016). Redox state and methods to evaluate oxidative stress in liver damage: From bench to bedside. Annals of Hepatology, 15(2), 160–173. doi: 10.5604/16652681.1193701. [DOI] [PubMed]
  49. De Matteis, S., et al. (2018). Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities. Oxidative Medicine and Cellular Longevity, 2018, 7512159. doi: 10.1155/2018/7512159. [DOI] [PMC free article] [PubMed]
  50. Andrisic, L., et al. (2018). Short overview on metabolomics approach to study pathophysiology of oxidative stress in cancer. Redox Biology, 14, 47–58. doi: 10.1016/j.redox.2017.08.009. [DOI] [PMC free article] [PubMed]
  51. Wang, B., et al. (2012). Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. Journal of Proteome Research, 11(2), 1217–1227. doi: 10.1021/pr2009252. [DOI] [PubMed]
  52. Fitian, A. I., & Cabrera, R. (2017). Disease monitoring of hepatocellular carcinoma through metabolomics. World Journal of Hepatology, 9(1), 1–17. doi: 10.4254/wjh.v9.i1.1. [DOI] [PMC free article] [PubMed]
  53. Assenat, E., et al. (2019). Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: The phase II randomised PRODIGE 10 trial. British Journal of Cancer, 120(9), 896–902. doi: 10.1038/s41416-019-0443-4. [DOI] [PMC free article] [PubMed]
  54. Huang, Q., et al. (2014). CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway. Journal of Hepatology, 61(4), 859–866. doi: 10.1016/j.jhep.2014.04.035. [DOI] [PubMed]
  55. Jin, J., et al. (2019). Hypo-phosphorylated CD147 promotes migration and invasion of hepatocellular carcinoma cells and predicts a poor prognosis. Cellular Oncology (Dordrecht), 42(4), 537–554. doi: 10.1007/s13402-019-00444-0. [DOI] [PubMed]

RESOURCES